Profile
Chantal van der Zwan joined Aescap in 2007, Prior to Aescap she held the position of Associate Director at NIBC Capital Partners, where she was responsible for origination, execution and management of private equity and mezzanine investments in North-Western Europe.
Her personal involvement focused on small- to medium-sized companies in the areas of Healthcare, Technology and Services.
After receiving her Medical Degree from the University of Leiden in 1996.
Chantal started her professional career at TNS NIPO as a project manager in the healthcare segment: coordinating market researches for the pharmaceutical industry and for healthcare institutions.
From 1998 to 2002, she worked as a strategic marketing consultant for the Consult branch of TNS NIPO, where she supported a broad range of companies in optimizing their marketing intelligence, reinforcing their competitive position and successfully introducing new products.
In 2003, Chantal received an MBA in International Economics and Management for SDA Bocconi and Anderson Business School.
Former positions of Chantal van der Zwan
Companies | Position | End |
---|---|---|
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Private Equity Investor | 2008-12-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Finance |
- Stock Market
- Insiders
- Chantal van der Zwan